Become a Readings Member to make your shopping experience even easier. Sign in or sign up for free!

Become a Readings Member. Sign in or sign up for free!

Hello Readings Member! Go to the member centre to view your orders, change your details, or view your lists, or sign out.

Hello Readings Member! Go to the member centre or sign out.

Understanding Amyotrophic Lateral Sclerosis
Paperback

Understanding Amyotrophic Lateral Sclerosis

$151.99
Sign in or become a Readings Member to add this title to your wishlist.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder marked by muscle weakness, atrophy, fasciculations, and spasticity due to motor neuron degeneration. Symptoms progress from focal weakness to difficulties in speaking, swallowing, and breathing, with eventual paralysis. The disease arises from mechanisms such as disrupted RNA metabolism (e.g., TDP-43 and FUS mutations), cytoskeletal and axonal transport defects (e.g., PFN1, TUBA4A mutations), excitotoxicity, and oxidative stress. While incurable, treatments like Riluzole and Edaravone can modestly slow progression, and supportive care-such as non-invasive ventilation, feeding tubes, and physical therapy-helps manage symptoms. Emerging therapies, including gene and RNA-targeted approaches, hold promise for the future.

Read More
In Shop
Out of stock
Shipping & Delivery

$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout

MORE INFO
Format
Paperback
Publisher
LAP Lambert Academic Publishing
Date
10 January 2025
Pages
60
ISBN
9786208420321

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder marked by muscle weakness, atrophy, fasciculations, and spasticity due to motor neuron degeneration. Symptoms progress from focal weakness to difficulties in speaking, swallowing, and breathing, with eventual paralysis. The disease arises from mechanisms such as disrupted RNA metabolism (e.g., TDP-43 and FUS mutations), cytoskeletal and axonal transport defects (e.g., PFN1, TUBA4A mutations), excitotoxicity, and oxidative stress. While incurable, treatments like Riluzole and Edaravone can modestly slow progression, and supportive care-such as non-invasive ventilation, feeding tubes, and physical therapy-helps manage symptoms. Emerging therapies, including gene and RNA-targeted approaches, hold promise for the future.

Read More
Format
Paperback
Publisher
LAP Lambert Academic Publishing
Date
10 January 2025
Pages
60
ISBN
9786208420321